The Principal Investment team targets investments in well-established life science companies with leading positions in attractive market segments and strong underlying growth drivers. Principal Investments operates out of Denmark (Copenhagen), the UK (London) and the US (Boston), investing in privately owned and publicly listed companies with a mix of control, co-control and minority positions. Novo Holdings’ Asia investment team, based in Singapore, works in close collaboration with our teams in Europe and the US. We look to invest USD 100-500+ million in each transaction, always with an engaged, supportive ownership agenda in mind.
In addition to capital and engagement, an investment from Novo Holdings also provides access to our extensive network within the life science industry. We use our experience and expertise from our ownership of world-leading life science companies to actively support a board and management in realizing their strategic ambitions.
At the end of 2022, the Principal Investments portfolio comprised 24 companies, with a total value of EUR 10 billion.